Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug 26:40:92-95.
doi: 10.1016/j.jdcr.2023.07.042. eCollection 2023 Oct.

Sudden-onset painful eruption of the hands: A cutaneous chimeric antigen receptor T-cell therapy reaction

Jimena A Miranda  1 , Charles Huvet  1 , Marie Donzel  2 , Anne Lazareth  3 , Jimmy Perrot  2 , Stéphane Dalle  1   4
Affiliations
Case Reports

Sudden-onset painful eruption of the hands: A cutaneous chimeric antigen receptor T-cell therapy reaction

Jimena A Miranda et al. JAAD Case Rep. .
No abstract available

Keywords: CAR T-cell therapy; adverse event; cutaneous toxic reaction.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Cutaneous CAR T-cell therapy—associated eruption presenting as violaceous-to-erythematous papules and plaques on dorsal (A) and palmar (B) surface of the hand.
Fig 2
Fig 2
Histopathology demonstrating perivascular lymphocytic infiltrate in the dermis in ×100 (A) and ×400 (B) magnification (H/E).
Fig 3
Fig 3
A, Imunohistochemical staining showing perivascular infiltrate cells positive for CD3 (red membranous dot-like pattern) and CD19 (brown membranous dot-like pattern) (red arrows). B, Closer view.
See this image and copyright information in PMC

References

    1. Bourbon E., Ghesquières H., Bachy E. CAR-T cells, from principle to clinical applications. Bull Cancer. 2021;108(10S):S4–S17. - PubMed
    1. Hirayama A.V., Turtle C.J. Toxicities of CD19 CAR-T cell immunotherapy. Am J Hematol. 2019;94(S1):S42–S49. - PubMed
    1. Nusbaum K.B., Dulmage B., Choi J.N., Jaglowski S.M., Korman A.M. Cutaneous manifestations of chimeric antigen receptor T-cell therapy: an introduction for dermatologists. J Am Acad Dermatol. 2022;87(3):597–604. - PubMed
    1. Min Lee C.K.M., Li S., Tran D.C., et al. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study. J Am Acad Dermatol. 2018;79(6):1047–1052. - PMC - PubMed
    1. Hu Y., Zheng W., Qiao J., et al. Bullous and exanthematous lesions associated with chimeric antigen receptor T-cell therapy in a patient with diffuse large B-cell lymphoma. JAMA Dermatol. 2020;156(9):1026–1028. - PubMed

Publication types

LinkOut - more resources